Author

K. S. Flatten

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Dobrovic· 1 shared A. E. Wahner Hendrickson· 1 shared A. Venkatachalam· 1 shared C. A. Ross· 1 shared C. Correia· 1 shared C. D. McGehee· 1 shared C. L. Scott· 1 shared E. M. Swisher· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dobrovic

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

R. M. Hurley, C. D. McGehee, K. Nesic, C. Correia, T. M. Weiskittel, R. L. Kelly, A. Venkatachalam, X. Hou, N. M. Pathoulas, X. W. Meng, O. Kondrashova, M. R. Radke, P. A. Schneider, K. S. Flatten, K. L. Peterson, , S. H. Kaufmann

This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.

bioRxiv · Dec 25, 2020Cancer Biology